Extension financing adds new investors, Janus Henderson Investors and RA Capital, with strong renewed participation from existing investors Proceeds will support further clinical development of lead program PHB-050 in food allergy and other atopic conditions Phase 1 clinical trial for PHB-050 remains on track Poplar Therapeutics, Inc., a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions, today announced the closing o

Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced a target discovery collaboration with Ono Pharmaceutical Co., Ltd. focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Under the agreement, Sinopia will apply its proprietary metabolomics-driven discovery platform to identify and validate novel therapeutic targets aimed a

Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetrabor

March 03, 2026 -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official launch following a period of stealth operations. The company is emerging with a Phase 1b/2a-ready clinical asset and the first close of its Seed financing. As part of its launch, Persevere has acquired the clinical-stage program and related assets for misetionamide (GP-2250) from Geistlich Pharma AG. Misetionamide is a novel, first-i

Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the first patient has been dosed in the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101, the company’s lead investigational program for the treatment of obesity. SYNT-101 is designed as a once-daily oral pill that redirects nutrient absorption past the small intestine’s duodenum, mimicking the effects of gastric bypass surgery. "Dosing o

Initial $50M Series A investment from founding investor RTW Investments Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune diseases March 03, 2026 -- Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced its launch with a $50 million Series A Financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. The financing was led by its foundin

225 Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Data from PAnTHa, the global Phase I first-in-human, dose-escalation study were presented during the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA Data support advancing 225Ac-PSMA-Trillium to the next phase of development Prostate cancer is the second most common

March 2, 2026 -- Efor, a global leader specializing in quality and compliance for the Life Sciences industry, today announced the acquisition of DynamixE, Inc., a U.S.-based company recognized for its expertise in Commissioning, Qualification & Validation (CQV), process engineering, automation and digitalization for pharmaceutical and biotechnology industries. Founded in 2013, Efor has built a leading international platform dedicated to quality and compliance for Life Sciences industries. With

In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo1 These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients1 The safety profile of risankizumab SC induction was consistent with its known profile in Crohn's di

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030 Companies to hold joint conference call on March 2, 2026 at 8:30 AM ET Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc